Serum Albumin, E.g., Bsa, Hsa, Etc. Patents (Class 530/363)
-
Patent number: 10866235Abstract: The invention relates to methods for binding biologically active molecules to surfaces by coating the surface with a supported reagent in a first step and then covalently coupling said biologically active molecules to the supported reagent using a biorthogonal cycloaddition reaction. Fields of application of the invention include biochemical research, medical diagnostics and the pharmaceutical industry.Type: GrantFiled: July 30, 2015Date of Patent: December 15, 2020Inventors: Vukic Soskic, Robert Poppe
-
Patent number: 10358462Abstract: The present invention relates to a method for the preparation of a solution of immunoglobulins based on an initial solution of immunoglobulins with a purity greater than or equal to 96% in the presence of a polyether or polymer of glycol, characterized in that it comprises the steps of: a) adding caprylic acid or salts of the same to the initial solution; b) adjusting the pH of the solution obtained in step a); c) incubating the solution obtained in step b) for the time and at a temperature necessary for the inactivation of enveloped viruses; d) performing a step of ultrafiltration/diafiltration on the solution obtained in step c).Type: GrantFiled: September 26, 2016Date of Patent: July 23, 2019Assignee: INSTITUTO GRIFOLS, S.A.Inventors: Pere Ristol Debart, Salvador Grancha Gamon, Juan Ignacio Jorquera Nieto, Maria Mercedes Faro Tomas, Nuria Jorba Grifols
-
Patent number: 10188713Abstract: This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided. In general, one aspect of this document features a composition comprising, or consisting essentially of, nucleic acid encoding HIF-2a, SOX-10, C-MYC, and TYRP-1, wherein the composition comprises less than 100 separate nucleic acid molecules.Type: GrantFiled: March 19, 2015Date of Patent: January 29, 2019Assignees: Mayo Foundation for Medical Education and Research, University of LeedsInventors: Richard G. Vile, Timothy J. Kottke, Jill M. Thompson, Jose S. Pulido, Alan A. Melcher, Peter Selby
-
Patent number: 10183984Abstract: A method for extracting recombinant human serum albumin (rHSA) from transgenic rice grain is provided, comprising the steps of: 1) grinding dehusked rice containing rHSA into milled rice grain with a fineness of 80˜120 mesh, which is mixed with a extraction buffer in a w/v ratio of 1:5, then extracting at 55˜60° C. for 1˜3 hours to obtain mixture I; said extraction buffer comprises 10˜30 mM phosphate buffer, 10˜20 mM sodium acetate, 15˜30 mM ammonium sulfate and 5˜20 mM sodium caprylate and has a pH of 6.5˜8; 2) adjusting the pH of mixture I to 4.0˜4.5, followed by precipitating at room temperature for 3˜12 hours to obtain mixture II; 3) filtering the mixture II and collecting the filtrate, to obtain a solution containing high concentration of rHSA. The concentration of rHSA in the resultant solution is 650˜660 ?g/mL, which increases by 1.15 times comparing to the extraction amount before improvement, and the amount of non-target protein is reduced by 2.46 times.Type: GrantFiled: January 14, 2016Date of Patent: January 22, 2019Assignee: Healthgen Biotechnology Corp.Inventors: Daichang Yang, Yang He, Guangfei Li
-
Patent number: 10179138Abstract: The present invention relates to a pharmaceutical composition comprising (a) 7?-hydroxycholesterol, (b) a water soluble organic solvent, preferably propylene glycol and/or DMSO, and (c) a solubilizing agent, preferably PEG hydrated castor oil, and to a method for preparing the same. This composition is suitable for preparing an intravenously administered preparation and comprises the pharmaceutically active substance ?-hydroxycholesterol, which is poorly soluble in water.Type: GrantFiled: January 12, 2017Date of Patent: January 15, 2019Assignee: IMMUNOPHARM AGInventors: Werner Bieberschulte, Christine Grimm, Rohan Charles Fernando
-
Patent number: 10016533Abstract: Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.Type: GrantFiled: March 13, 2017Date of Patent: July 10, 2018Inventor: Meng Chen
-
Patent number: 9855325Abstract: The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype Ia conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein; d) a conjugate that is a capsular saccharide from GBS serotype II conjugated to a carrier protein; and e) a conjugate that is a capsular saccharide from GBS serotype V conjugated to a carrier protein.Type: GrantFiled: October 3, 2013Date of Patent: January 2, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Patent number: 9603978Abstract: Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.Type: GrantFiled: December 17, 2015Date of Patent: March 28, 2017Inventor: Meng Chen
-
Methods and compositions of nucleic acid ligands for detection of foodborne and waterborne pathogens
Patent number: 9562900Abstract: Specific DNA sequences for binding various foodborne and waterborne pathogens and biotoxins are described. Each of these sequences can function in varying assay and sensor formats with varying degrees of success.Type: GrantFiled: August 11, 2011Date of Patent: February 7, 2017Assignee: OTC Biotechnologies, LLCInventor: John G. Bruno -
Patent number: 9506920Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.Type: GrantFiled: July 21, 2014Date of Patent: November 29, 2016Assignee: Nestec S.A.Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund
-
Patent number: 9149541Abstract: A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain having and amino terminus end (A1) and an acid terminus end (A2) of the protein or polypeptide and having a weight average molecular weight equal to or greater than 10,000 Daltons (10 kDa), wherein the conjugate comprises a number m of tyrosine conjugates (modified tyrosine residues) as depicted in Formula (I-A) or (I), where m is at least one and is less than or equal to n: where X, Lg, L and R are as defined herein.Type: GrantFiled: July 5, 2012Date of Patent: October 6, 2015Assignee: NOVARTIS AGInventors: Roberto Adamo, Martin Allen, Francesco Berti, Elisa Danieli, Qi-Ying Hu
-
Publication number: 20150147325Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: ApplicationFiled: February 6, 2015Publication date: May 28, 2015Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
-
Publication number: 20150147324Abstract: This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are a Fe polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: ApplicationFiled: February 6, 2015Publication date: May 28, 2015Inventors: John C. Timmer, Brendan P. Eckelman, Grant B. Guenther, Peter L. Nguy, Henry Chan, Quinn Deveraux
-
Publication number: 20150125423Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: January 12, 2015Publication date: May 7, 2015Inventors: Jennifer Mitcham, Matthew Moyle
-
Patent number: 9023797Abstract: Described herein are methods for inactivating viruses using caprylate in solutions containing albumin.Type: GrantFiled: July 25, 2013Date of Patent: May 5, 2015Assignee: Grifols, S.A.Inventors: Wytold Lebing, Doug Burns, Nathan Roth, Joann Hotta
-
Publication number: 20150118240Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: ApplicationFiled: May 13, 2013Publication date: April 30, 2015Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
-
Publication number: 20150104818Abstract: The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.Type: ApplicationFiled: December 19, 2014Publication date: April 16, 2015Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Publication number: 20150094267Abstract: The present invention relates to succinimide-activated nitroxyl compounds and methods for the synthesis of such compounds. The present invention also relates to the use of succinimide-activated nitroxyl compounds to prepare nitroxylated proteins, for example nitroxylated heme proteins (e.g., nitroxylated hemoglobin and nitroxylated myoglobin). The nitroxylated proteins are optionally also conjugated to a polyalkylene oxide (PAO), for example to a polyethylene glycol (PEG). Polynitroxylated heme proteins are useful as oxygen therapeutic agents (OTAs). The invention further relates to pharmaceutical compositions of the nitroxylated proteins and methods for the use of nitroxylated proteins in the treatment of various conditions.Type: ApplicationFiled: March 15, 2013Publication date: April 2, 2015Inventors: Kim D. Vandegriff, Ashok Malavalli, Gnel Mkrtchyan
-
Publication number: 20150087586Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise conjugated C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.Type: ApplicationFiled: March 25, 2013Publication date: March 26, 2015Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Patent number: 8986688Abstract: This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide, a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are an Fc polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: GrantFiled: June 28, 2012Date of Patent: March 24, 2015Assignee: InhibRx, LLCInventors: John Timmer, Brendan Eckelman, Grant B. Guenther, Peter L. Nguy, Henry Chan, Quinn Deveraux
-
Patent number: 8980266Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: GrantFiled: June 28, 2012Date of Patent: March 17, 2015Assignee: InhibRx, LLCInventors: Brendan Eckelman, John Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
-
Publication number: 20150072919Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Hui WEI, Aaron P. YAMNIUK, Vidhyashankar RAMAMURTHY, Alexander T. KOZHICH, Martin J. CORBETT, Stanley Richard KRYSTEK, JR.
-
Publication number: 20150065687Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: March 15, 2013Publication date: March 5, 2015Inventor: Karen Ann Delahay
-
Publication number: 20150051375Abstract: A bonding method is provided for gold nanoparticles (GNPs). GNPs are bonded with diethylenetriamine pentaacetic acid (DTPA). GNPs have high bio-compatibility and high surface area. Hence, the present invention uses GNPs as carriers for diagnosing and treating cancer.Type: ApplicationFiled: August 13, 2013Publication date: February 19, 2015Applicant: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C.Inventors: Chun-Chia Cheng, Shiau-Shiun Guan
-
Publication number: 20150050713Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: July 25, 2014Publication date: February 19, 2015Inventors: Michael P. Malakhov, Fang Fang
-
Publication number: 20150045302Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.Type: ApplicationFiled: March 14, 2013Publication date: February 12, 2015Inventors: Angelo Corti, Flavio Curnis
-
Publication number: 20150038681Abstract: A method of preparing a product, preferably in the form of a functionalized high molecular weight component such as, for example, a functionalized protein includes passing a first liquid comprising a component A along one side of a semi-permeable membrane and passing a second liquid comprising a component B along another, preferably opposing, side of the membrane, wherein the membrane excludes passage of component A but allows passage of component B, and after passage of component B through the membrane, a chemical reaction takes place between component A and component B, preferably with the formation of covalent bonds.Type: ApplicationFiled: August 4, 2014Publication date: February 5, 2015Inventors: Juergen Mollenhauer, Heinz W. Joseph, Helmut Wurst
-
Patent number: 8946167Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: February 9, 2009Date of Patent: February 3, 2015Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20150031604Abstract: The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Frederic ZECRI, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Jun Yuan, Aimee Richardson USERA, Changgang LOU, Aaron KANTER, Alexandra Marshall BRUCE, Carla Giumaraes
-
Publication number: 20150030594Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes
-
Publication number: 20150024456Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.Type: ApplicationFiled: July 30, 2014Publication date: January 22, 2015Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
-
Patent number: 8933199Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: January 13, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Martin J. Corbett, Alexander T. Kozhich
-
Patent number: 8927694Abstract: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.Type: GrantFiled: October 14, 2009Date of Patent: January 6, 2015Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Charlotte McDonagh, Michael Feldhaus, Alexandra Huhalov
-
Publication number: 20140370046Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: ApplicationFiled: May 9, 2012Publication date: December 18, 2014Applicant: Biothera, Inc.Inventors: Nandita Bose, Anissa S.H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Patent number: 8906633Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.Type: GrantFiled: December 20, 2011Date of Patent: December 9, 2014Assignee: Randox Laboratories LimitedInventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
-
Publication number: 20140357564Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.Type: ApplicationFiled: February 14, 2013Publication date: December 4, 2014Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
-
Publication number: 20140349929Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: March 28, 2014Publication date: November 27, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
-
Patent number: 8889830Abstract: A novel hemoglobin-albumin complex which has high stability of the oxygenated form, has high biocompatibility, and is easily prepared (synthesized), and an artificial plasma expander and an artificial oxygen carrier containing the complex are provided. The hemoglobin-albumin complex of the invention is characterized by having hemoglobin as the core, and albumin as the shell bound via a crosslinker to the above hemoglobin. Also, the artificial oxygen carrier of the invention is characterized by containing the hemoglobin-albumin complex of the invention.Type: GrantFiled: February 20, 2012Date of Patent: November 18, 2014Assignee: Chuo UniversityInventors: Teruyuki Komatsu, Daiki Tomita
-
Publication number: 20140322306Abstract: The invention provides a molecule that inhibits or prevents an interaction between a Src family kinase and an androgen or estradiol receptor, for use in preventing or treating a non-cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject, or for use in preventing or treating a cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject who wishes to preserve fertility, or for use in preventing or treating a gynaecological condition in which an activity of AR and/or ER is a contributory factor in a subject.Type: ApplicationFiled: November 1, 2012Publication date: October 30, 2014Inventors: Mark Eccleston, Satu Vainikka, George Steven Morris
-
Publication number: 20140323688Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.Type: ApplicationFiled: June 24, 2014Publication date: October 30, 2014Inventor: Andrew Lees
-
Publication number: 20140316110Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.Type: ApplicationFiled: June 24, 2014Publication date: October 23, 2014Inventor: Andrew Lees
-
Publication number: 20140315816Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20140315817Abstract: The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.Type: ApplicationFiled: November 18, 2012Publication date: October 23, 2014Applicant: ELEVEN BIOTHERAPEUTICS, INC.Inventors: Michael March Schmidt, Eric Steven Furfine, Amy Jada Andreucci, Thomas M. Barnes
-
Publication number: 20140316111Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyanoimidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.Type: ApplicationFiled: June 24, 2014Publication date: October 23, 2014Inventor: Andrew Lees
-
Patent number: 8865647Abstract: If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection.Type: GrantFiled: November 1, 2010Date of Patent: October 21, 2014Assignee: Novo Nordisk A/SInventors: Helle Naver, Svend Havelund, Peter Madsen
-
Publication number: 20140309163Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: May 12, 2014Publication date: October 16, 2014Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Martin J. Corbett, Alexander T. Kozhich
-
Patent number: 8859499Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.Type: GrantFiled: March 12, 2013Date of Patent: October 14, 2014Assignees: Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of CaliforniaInventors: Seetharama A. Acharya, Marcos Intaglietta
-
Patent number: 8859724Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.Type: GrantFiled: April 26, 2007Date of Patent: October 14, 2014Assignee: B. Braun Melsungen AGInventors: Bernd H. Meier, Nele Meier
-
Publication number: 20140302618Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.Type: ApplicationFiled: May 22, 2014Publication date: October 9, 2014Applicant: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Publication number: 20140302554Abstract: A compound may generally comprise the formula: wherein R1 is independently selected from C2-C10 alkyl or substituted alkyl, R2 is independently selected from the group consisting of —H and C1-C6 alkyl or substituted alkyl, X is selected from the group consisting of —NH— and —O—, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Matthew Jacob Powell, Trust T. Razunguzwa, Miaosheng Li